CytoDyn shares plummet after FDA blasts the biotech for cherry picking COVID-19 data

Retrieved on: 2021-05-17 20:48:45

Tags for this article:

Health sciences

Leronlimab

Health

Medical research

Pharmaceutical industry

Clinical research

Drug discovery

Food and Drug Administration

CCR5 receptor antagonist

Adam Feuerstein

Click the tags to see associated articles and topics

CytoDyn shares plummet after FDA blasts the biotech for cherry picking COVID-19 data. View article details on hiswai:

Excerpt

But the company instead focused its data release on a subgroup of 62 mechanically ventilated, critically ill COVID-19 patients, claiming that the drug ...

Article found on: www.fiercebiotech.com

View Original Article